ESR1 and neoplasm: However, the almost all of the patients with ER+ IGF1Rstrong tumors received endocrine treatment, which may reflect more aggressive tumor features, compared to a significantly lower proportion of endocrine-treated patients with ER+ IGF1Rnot strong tumors.